Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

BeiGene Out-Licenses Second Molecule to Merck Serono in $232 Million Deal

publication date: Nov 13, 2013
BeiGene, an innovative Beijing biopharma, has out-licensed the ex-China rights for a second novel cancer treatment to Merck Serono. The terms of the latest deal exactly mirror the first. BeiGene retains China development and commercialization rights to a PARP inhibitor that it discovered, while Merck Serono will develop the drug in the rest of the world. BeiGene received an undisclosed upfront payment and is line to receive up to $232 million in development and commercial milestones. In addition, BeiGene will receive worldwide royalties on sales. In May, the two companies entered a similar deal for BeiGene’s second generation BRAF inhibitor. More details....

Stock Symbol: (Xetra: MRK)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital